CETROTIDE (cetrorelix acetate) by Gland Pharma is clinical pharmacology gnrh induces the production and release of luteinizing hormone (lh) and follicle stimulating hormone (fsh) from the gonadotrophic cells of the anterior pituitary. First approved in 2000.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Cetrotide (cetrorelix acetate) is a GnRH antagonist administered subcutaneously that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to prevent premature ovulation during controlled ovarian stimulation for assisted reproductive technologies. It works by competing with natural GnRH for pituitary receptor binding, providing rapid onset of LH suppression (1–2 hours) with reversible effects upon discontinuation.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand and commercial teams face near-term transition planning and potential headcount rationalization.
CLINICAL PHARMACOLOGY GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This…
Worked on CETROTIDE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)
Working on Cetrotide offers exposure to reproductive endocrinology and specialty pharmaceutical marketing in a niche therapeutic area with established clinical utility. However, the LOE-approaching lifecycle stage means career growth is constrained; roles will increasingly focus on competitive defense, cost management, and transition planning rather than expansion.